[ad_1]
Here’s a roundup of top developments in the biotech space over the last 24 hours:
Mersana, GSK Ink $1.36B Biobuck Deal For Cancer-Focused Therapy
Mersana Therapeutics Inc MRSN announced a global collaboration that provides GSK plc GSK an exclusive option to co-develop and commercialize XMT-2056.
Mersana will receive an upfront option purchase fee of $100 million. Mersana is also eligible to receive up to $1.36 billion in the form of an option exercise payment and development, regulatory and commercial milestone payments if GSK exercises its option.
Mersana has retained options to profit-share and to co-promote in the U.S.
Clearside Biomedical Secures Non-Dilutive fUNDING fROM HealthCare Royalty Partners
Clearside Biomedical Inc CLSD has entered into a Royalty Interest Purchase and Sale Agreement with HealthCare Royalty Partners.
Under the terms of the agreement, Clearside will receive an initial payment of $32.5 million. At the same time, an additional $12.5 million will be deposited in an escrow account to be released to Clearside upon attainment of a pre-specified sales milestone for XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use.
The terms of the agreement also provide for an additional milestone payment of $20 million to Clearside upon attainment of a second pre-specified 2024 sales milestone for XIPERE.
Opiant Pharma Secures Additional BARDA Funding For Opioid Overdose Treatment
The Biomedical Advanced Research and Development Authority (BARDA) has awarded an additional approximately $2.1 million to Opiant Pharmaceuticals Inc OPNT to support OPNT003, nasal nalmefene, for opioid overdose.
The increase in funding is primarily directed toward preparing and filing a marketing application for OPNT003 to the FDA.
CorMedix Slapped With Second FDA Rejection For DefenCath
CorMedix Inc CRMD received a second Complete Response Letter (CRL) from the FDA for DefenCath, developed as a catheter lock solution to reduce catheter-related bloodstream infections.
The letter states that DefenCath cannot be approved until deficiencies related to the contract manufacturing organization and the supplier of the active pharmaceutical ingredient heparin during inspections are resolved to the satisfaction of the FDA.
Shares are down 54.1% at $3.45 during the premarket session.
Pfizer, Valneva Kickstart Late-Stage Study For Lyme Disease Vaccine
Pfizer Inc PFE and Valneva SE VALN have initiated a Phase 3 study for Lyme disease vaccine candidate VLA15.
The randomized, placebo-controlled, Phase 3 VALOR study will enroll approximately 6,000 participants 5 years and older.
Pending successful completion of the Phase 3 study, Pfizer could submit marketing applications to the FDA and European Medicines Agency in 2025.
Pfizer will make a $25 million milestone payment to Valneva upon initiating the Phase 3 study.
Zealand To Cease Trading On US Stock Exchange
Zealand Pharma A/S ZEAL has notified its intention to remove its American Depositary Shares from listing on NASDAQ voluntarily.
The company’s ordinary shares will continue to be listed on Nasdaq Copenhagen, which is the primary source of liquidity and trading flexibility for Zealand shares.
The decision is part of Zealand’s refocused strategy to prioritize R&D and streamline corporate operations.
Moderna, Europe Amend COVID-19 Pact For Supply Of Omicron-Targeted Vaccine
Moderna Inc MRNA amended its agreement with the European Commission (EC) to convert contractually agreed doses of Moderna’s COVID-19 vaccine to its omicron-containing bivalent vaccines for supply in 2022, pending regulatory approval.
In addition, the EC has agreed to purchase an additional 15 million doses of Omicron-containing vaccine booster candidates.
Under the amendment, contractually scheduled doses in July and August of Moderna’s COVID-19 vaccine will be deferred to later in 2022.
Moderna is advancing two bivalent candidates. Both bivalent candidates contain 25 µg of the currently authorized booster (mRNA-1273) and 25 µg of an Omicron-specific subvariant.
AstraZeneca’s Dato-DXd-Based Combo Therapies Show Promising Activity In Lung Cancer Patients
AstraZeneca Plc AZN reported initial results from the TROPION-Lung02 phase 1b trial showing that datopotamab deruxtecan (Dato-DXd) combo therapies demonstrated promising clinical activity and a tolerable safety profile in non-small cell lung cancer (NSCLC) without actionable genomic alterations.
The interim analysis demonstrated an overall response rate in the overall population of 37% in patients receiving datopotamab deruxtecan plus Merck & Co Inc’s Keytruda (pembrolizumab) (doublet therapy).
The data showed an ORR of 41% in patients receiving datopotamab deruxtecan plus pembrolizumab and platinum chemotherapy (triplet therapy).
Beigene’s Liver Cancer Candidate At Par With Bayer’s Drug
BeiGene Ltd’s BGNE global Phase 3 RATIONALE 301 trial with tislelizumab met its primary endpoint of non-inferior Overall Survival (OS) versus sorafenib as a first-line treatment for unresectable hepatocellular carcinoma (HCC).
The safety profile for tislelizumab was consistent with previous studies, and no new safety signals were reported.
HCC (a form of liver cancer) is the sixth most common cancer worldwide.
Offering
Aytu BioPharma Inc AYTU launched an underwritten public offering. Details are yet to be determined.
Karuna Therapeutics Inc KRTX commenced an underwritten public offering of $600 million, and underwriters can purchase an additional $90 million.
CinCor Pharma Inc CINC has launched an underwritten public offering of 6 million shares.
On The Radar
Earnings
Dare Bioscience Inc DARE: Before the market open.
Intra-Cellular Therapies Inc ITCI: Before the market open.
Rubius Therapeutics Inc RUBY: Before the market open.
Syros Pharmaceuticals Inc SYRS: Before the market open.
Beam Therapeutics Inc BEAM: Before the market open.
Verve Therapeutics Inc VERV: Before the market open.
Axsome Therapeutics Inc AXSM: Before the market open.
Ionis Pharmaceuticals Inc IONS: Before the market open.
Eagle Pharmaceuticals Inc EGRX: Before the market open.
Vir Biotechnology Inc VIR: After market close.
Inovio Pharmaceuticals Inc INO: After market close.
Exelixis Inc EXEL: After market close.
Arcturus Therapeutics Holdings Inc ARCT: After market close.
[ad_2]
Image and article originally from www.benzinga.com. Read the original article here.